Venus Remedies Limited

BSE: 526953 NSE: VENUSREM
Venus Remedies Limited - pharma in Chandigarh, Chandigarh, India. FY 2026 financials and compliance.
CIN L24232CH1989PLC009705 Incorporated 15 September 1989 ROC Chandigarh HQ Chandigarh, Chandigarh, India
Active Listed - NSE: VENUSREM · BSE: 526953 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹769.6 Cr
▲ 18.79% YoY
EBITDA · FY 2026
₹159.86 Cr
▲ 89.18% YoY
Net profit · FY 2026
₹102.78 Cr
▲ 126.79% YoY
Authorised capital
₹20 Cr
Registered with MCA
Paid-up capital
₹13.37 Cr
Issued & subscribed
Open charges
None
Satisfied ₹909.48 Cr
Company age
37 yrs
Est. 1989
Employees · EPFO
1,119
Latest available

About Venus Remedies Limited

Data last updated: 02 June 2026

Venus Remedies Limited is a public limited company based in Chandigarh, Chandigarh, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 15 September 1989, the company has been in operation for over 37 years.

Registered with ROC Chandigarh under CIN L24232CH1989PLC009705. Listed on BSE: 526953 and NSE: VENUSREM.

Capital: an authorised share capital of ₹20 Cr and a paid-up capital of ₹13.37 Cr. Formerly known as Venus Glucose Private Limited. It is led by directors including Manu Chaudhary and Akshansh Chaudhary.

Last AGM: 22 August 2025. Financial statements filed for year ended 31 March 2025. Office: Sco 857 2Nd Floor C. No. 10 Nac Manimajra, Chandigarh, Chandigarh, India – 160101.

As per the financials filed for FY 2025, the company reported a revenue of ₹668.84 Cr, a growth of 9% compared to the previous year.

The company has a workforce of approximately 1,119 employees as per the latest available data.

The company is associated with 2 brands - Venus Medicine Research Center, Venus Remedies. As per MCA filings, the company has satisfied charges of ₹909.48 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website venusremedies.com.

Company Details of Venus Remedies Limited
CIN L24232CH1989PLC009705
Registration Number 009705
Incorporation Date 15 September 1989
ROC Chandigarh
Listing Status Listed (BSE: 526953, NSE: VENUSREM)
Company Status Active
Date of Last AGM 22 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Pawan Chaudhary Managing Director Manu Chaudhary Whole-Time Director Akshansh Chaudhary Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    venusremedies.com
  • Social Media
  • Registered Address
    Sco 857 2Nd Floor C. No. 10 Nac Manimajra, Chandigarh, Chandigarh, India – 160101
  • Industry
    Pharma, Drug Formulation & Development
Company report
Venus Remedies Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Venus Remedies Limited report

Financials, compliance, directors, charges, ownership and filings for Venus Remedies Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Venus Remedies Limited

Venus Remedies Limited has one previous CIN (Corporate Identification Number): L24232CH1989PTC009705. The current CIN is L24232CH1989PLC009705, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24232CH1989PLC009705 Current
L24232CH1989PTC009705 Previous

Associated Brands with Venus Remedies Limited

Venus Remedies Limited operates two associated brands: Venus Medicine Research Center and Venus Remedies. These brands represent Venus Remedies Limited's diversified market presence and brand portfolio.

Brand Description Website
Venus Medicine Research Center
Delivers specialized bio-analytical services for drug development and research applications. vmrcindia.com
Venus Remedies
Research-based generic and antibiotic pharmaceuticals are manufactured. venusremedies.com

Business Activity of Venus Remedies Limited

Venus Remedies Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Venus Remedies Limited

Venus Remedies Limited is audited by J K Jain Associates (ICAI peer reviewed, certificate valid till 2027-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
J K Jain Associates (ICAI peer reviewed, certificate valid till 2027-04-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Venus Remedies Limited

Venus Remedies Limited is currently managed by 12 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Manu Chaudhary
Also directs: Venus Remedies Limited, Sunev Pharma Solutions Limited
Whole-Time Director 10 Oct 2005 20 Years 9 Months Current
Akshansh Chaudhary
Also directs: Venus Remedies Limited, Spine Software Systems Private Limited
Whole-Time Director 27 May 2022 4 Years 1 Months Current
Jagdish Chander Sharma
Also directs: Venus Remedies Limited, Himachal Pradesh Beverages Limited
Director 13 Aug 2024 1 Years 10 Months Current
Npsingh Monga
Also directs: Venus Remedies Limited, Assetric Ventures Llp
Director 29 May 2023 3 Years 1 Months Current
Navdeep Sud
Also directs: Venus Remedies Limited
Director 20 Jun 2020 6 Years 0 Months Current
Ashutosh Jain
Also directs: Venus Remedies Limited, Sunev Pharma Solutions Limited
Whole-Time Director 01 May 2007 19 Years 2 Months Current
Showing 6 of 12 current directors. View all directors

Financials of Venus Remedies Limited FY 2026 filings available

Venus Remedies Limited reported revenue of ₹769.6 Cr (up 18.79% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹769.6 Cr ▲ 18.79%
Profit · FY 2026
₹102.78 Cr ▲ 126.79%
EBITDA · FY 2026
₹159.86 Cr ▲ 89.18%
Revenue₹ Cr · Consolidated05001,000FY 2020: ₹341 Cr341FY 2020FY 2021: ₹548 Cr · +60.5% YoY548+60.5%FY 2021FY 2022: ₹599 Cr · +9.2% YoY599+9.2%FY 2022FY 2023: ₹556 Cr · -7.2% YoY556-7.2%FY 2023FY 2024: ₹601 Cr · +8.3% YoY601+8.3%FY 2024FY 2025: ₹648 Cr · +7.7% YoY648+7.7%FY 2025FY 2026: ₹770 Cr · +18.8% YoY770+18.8%FY 2026
Net Profit₹ Cr · Consolidated-50050100150FY 2020: ₹10 Cr (loss)-10FY 2020FY 2021: ₹62 Cr · +717.8% YoY61.8+717.8%FY 2021FY 2022: ₹41 Cr · -34.1% YoY40.7-34.1%FY 2022FY 2023: ₹27 Cr · -34.8% YoY26.6-34.8%FY 2023FY 2024: ₹28 Cr · +7.2% YoY28.5+7.2%FY 2024FY 2025: ₹45 Cr · +59% YoY45.3+59%FY 2025FY 2026: ₹103 Cr · +126.8% YoY103+126.8%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0100200300Q1'25: ₹109 Cr · +14.1% YoY109+14.1%Q1'25Q2'25: ₹167 Cr · -0.2% YoY167-0.2%Q2'25Q3'25: ₹177 Cr · +23.3% YoY177+23.3%Q3'25Q4'25: ₹195 Cr · -0.1% YoY195-0.1%Q4'25Q1'26: ₹132 Cr · +21.4% YoY132+21.4%Q1'26Q2'26: ₹193 Cr · +15.1% YoY193+15.1%Q2'26Q3'26: ₹180 Cr · +1.9% YoY180+1.9%Q3'26Q4'26: ₹259 Cr · +33% YoY259+33%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹769.6 Cr ₹647.89 Cr ₹601.45 Cr ₹555.51 Cr ₹598.65 Cr ₹548.12 Cr ₹341.46 Cr
Other Income ₹12.58 Cr ₹20.96 Cr ₹11.58 Cr ₹10.32 Cr ₹8.31 Cr ₹19.63 Cr ₹5.31 Cr
Total Income ₹782.18 Cr ₹668.85 Cr ₹613.03 Cr ₹565.83 Cr ₹606.96 Cr ₹567.75 Cr ₹346.77 Cr
Cost of Materials Consumed ₹387.98 Cr ₹348.77 Cr ₹344.28 Cr ₹317.79 Cr ₹381.97 Cr ₹347.94 Cr ₹168.46 Cr
Purchases of Stock-in-Trade ₹10.76 Cr ₹25.04 Cr ₹13.07 Cr ₹5.16 Cr ₹0 ₹0 ₹0
Changes in Inventories -₹11.47 Cr ₹4.81 Cr -₹2.66 Cr ₹8.04 Cr ₹3.48 Cr -₹7.15 Cr ₹5.86 Cr
Employee Benefit Expense ₹88.68 Cr ₹80.49 Cr ₹71.5 Cr ₹61.33 Cr ₹52.33 Cr ₹46.02 Cr ₹46.02 Cr
Finance Costs ₹4 Lakh ₹7 Lakh ₹9.4 Lakh ₹29 Lakh ₹48.1 Lakh ₹13.02 Cr ₹13.34 Cr
Depreciation & Amortisation ₹25.67 Cr ₹22.51 Cr ₹26.44 Cr ₹32.3 Cr ₹33.53 Cr ₹35.28 Cr ₹32.01 Cr
Other Expenses ₹146.37 Cr ₹125.24 Cr ₹115.66 Cr ₹102.99 Cr ₹98.76 Cr ₹107.54 Cr ₹80.31 Cr
Total Expenses ₹648.03 Cr ₹606.93 Cr ₹568.38 Cr ₹527.9 Cr ₹570.55 Cr ₹542.64 Cr ₹345.99 Cr
Profit Before Exceptional Items & Tax ₹134.15 Cr ₹61.92 Cr ₹44.65 Cr ₹37.93 Cr ₹36.41 Cr ₹25.11 Cr ₹77.8 Lakh
Exceptional Items ₹0 ₹9.91 Cr ₹0 ₹0 ₹0 ₹23.44 Cr -₹8.81 Cr
Profit Before Tax ₹134.15 Cr ₹71.83 Cr ₹44.65 Cr ₹37.93 Cr ₹36.41 Cr ₹48.55 Cr -₹8.03 Cr
Total Tax Expense ₹31.37 Cr ₹23.58 Cr ₹16.15 Cr ₹11.36 Cr -₹4.32 Cr -₹13.21 Cr ₹1.96 Cr
Net Profit ₹102.78 Cr ₹45.32 Cr ₹28.5 Cr ₹26.57 Cr ₹40.72 Cr ₹61.77 Cr -₹10 Cr
  attributable to Owners ₹0 - ₹27.22 Cr ₹0 ₹0 ₹0 ₹0
  attributable to NCI ₹0 - ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income ₹1 Lakh -₹68 Lakh -₹1.28 Cr -₹6.71 Cr -₹56.2 Lakh -₹9.5 Lakh -₹47.2 Lakh
Total Comprehensive Income ₹102.79 Cr ₹44.64 Cr ₹27.22 Cr ₹19.86 Cr ₹40.16 Cr ₹61.67 Cr -₹10.47 Cr
EBITDA (computed) ₹159.86 Cr ₹84.5 Cr ₹71.18 Cr ₹70.52 Cr ₹70.42 Cr ₹73.41 Cr ₹46.13 Cr
Basic EPS ₹76.89 ₹33.90 ₹21.31 ₹19.88 ₹30.86 ₹50.04 ₹-8.10
Diluted EPS ₹76.89 ₹33.90 ₹21.31 ₹19.88 ₹30.86 ₹50.04 ₹-8.10
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹853.71 Cr ₹715.72 Cr ₹626.83 Cr ₹601.08 Cr
Non-current Assets ₹458.5 Cr ₹264 Cr ₹267.3 Cr ₹278.12 Cr
Current Assets ₹395.21 Cr ₹451.72 Cr ₹359.53 Cr ₹322.96 Cr
Property, Plant & Equipment ₹125.43 Cr ₹124.7 Cr ₹133.32 Cr ₹136.72 Cr
Inventories ₹129.37 Cr ₹100.49 Cr ₹121.69 Cr ₹119.94 Cr
Trade Receivables ₹103.28 Cr ₹112.22 Cr ₹80.5 Cr ₹76.66 Cr
Cash & Equivalents ₹25.12 Cr ₹57.52 Cr ₹48.96 Cr ₹21.21 Cr
Equity (Net Worth) ₹663.75 Cr ₹560.95 Cr ₹487.55 Cr ₹460.34 Cr
Equity Share Capital ₹13.37 Cr ₹13.37 Cr ₹13.37 Cr ₹13.37 Cr
Borrowings (Non-current) ₹0 ₹0 ₹38.68 Cr ₹38.68 Cr
Borrowings (Current) ₹0 ₹1.69 Cr ₹2.65 Cr ₹3.61 Cr
Total Debt (computed) ₹0 ₹1.69 Cr ₹41.33 Cr ₹42.29 Cr
Current Liabilities ₹161.76 Cr ₹136.29 Cr ₹79.42 Cr ₹82.57 Cr
Total Liabilities ₹189.96 Cr ₹154.77 Cr ₹139.28 Cr ₹140.74 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹155.76 Cr ₹86.45 Cr ₹37.28 Cr ₹36.62 Cr ₹41 Cr
Investing Cash Flow -₹181.56 Cr -₹76.25 Cr -₹7.21 Cr -₹50.83 Cr -₹16.63 Cr
Financing Cash Flow -₹3.12 Cr -₹1.02 Cr -₹1.08 Cr -₹57 Lakh -₹9.48 Cr
Capital Expenditure ₹37.65 Cr ₹9.63 Cr ₹9.32 Cr ₹7.82 Cr ₹13.71 Cr
Free Cash Flow (computed) ₹118.11 Cr ₹76.82 Cr ₹27.96 Cr ₹28.8 Cr ₹27.29 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹32.41 Cr ₹8.56 Cr ₹27.74 Cr -₹22.05 Cr ₹14.38 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹259.4 Cr ₹180.26 Cr ₹192.75 Cr ₹131.9 Cr ₹194.97 Cr ₹176.86 Cr ₹167.45 Cr ₹108.61 Cr ₹195.16 Cr ₹143.42 Cr ₹167.72 Cr ₹95.15 Cr
Other Income ₹4.95 Cr ₹2.52 Cr ₹1.71 Cr ₹8.69 Cr ₹6.76 Cr ₹2.03 Cr ₹10.58 Cr ₹1.59 Cr ₹3.92 Cr ₹2.35 Cr ₹3.05 Cr ₹2.26 Cr
Total Income ₹264.35 Cr ₹182.78 Cr ₹194.46 Cr ₹140.59 Cr ₹201.73 Cr ₹178.89 Cr ₹178.03 Cr ₹110.2 Cr ₹199.08 Cr ₹145.77 Cr ₹170.77 Cr ₹97.41 Cr
Cost of Materials Consumed ₹116.28 Cr ₹93.86 Cr ₹106.51 Cr ₹71.33 Cr ₹104.21 Cr ₹97.52 Cr ₹77.46 Cr ₹69.58 Cr ₹84.17 Cr ₹87.31 Cr ₹95.17 Cr ₹77.63 Cr
Purchases of Stock-in-Trade ₹4.73 Cr ₹1.9 Cr ₹1.86 Cr ₹2.27 Cr ₹2.13 Cr ₹5.5 Cr ₹8.38 Cr ₹9.03 Cr ₹2.67 Cr ₹2.63 Cr ₹4.6 Cr ₹3.17 Cr
Changes in Inventories -₹1.45 Cr -₹9.51 Cr -₹1.06 Cr ₹55 Lakh -₹3.28 Cr ₹7.18 Cr ₹21.89 Cr -₹20.98 Cr ₹33.2 Cr -₹75 Lakh -₹2.25 Cr -₹32.86 Cr
Employee Benefit Expense ₹24.56 Cr ₹20.83 Cr ₹22.97 Cr ₹20.3 Cr ₹21.16 Cr ₹19.55 Cr ₹21.57 Cr ₹18.21 Cr ₹19.71 Cr ₹17.35 Cr ₹18.51 Cr ₹15.94 Cr
Finance Costs ₹1 Lakh ₹1 Lakh ₹1 Lakh ₹1 Lakh ₹1 Lakh ₹1 Lakh ₹2 Lakh ₹2 Lakh ₹2 Lakh ₹7 Lakh ₹6 Lakh ₹6 Lakh
Depreciation & Amortisation ₹6.76 Cr ₹6.56 Cr ₹6.17 Cr ₹6.18 Cr ₹4.71 Cr ₹5.41 Cr ₹6.4 Cr ₹5.98 Cr ₹5.91 Cr ₹6.54 Cr ₹6.44 Cr ₹7.55 Cr
Other Expenses ₹51.86 Cr ₹35.66 Cr ₹31.51 Cr ₹27.34 Cr ₹41.75 Cr ₹28.75 Cr ₹33.24 Cr ₹21.51 Cr ₹35.94 Cr ₹24.84 Cr ₹33.9 Cr ₹20.87 Cr
Total Expenses ₹202.75 Cr ₹149.31 Cr ₹167.97 Cr ₹127.98 Cr ₹170.69 Cr ₹163.92 Cr ₹168.96 Cr ₹103.35 Cr ₹181.62 Cr ₹137.99 Cr ₹156.43 Cr ₹92.36 Cr
Profit Before Exceptional Items & Tax ₹61.6 Cr ₹33.47 Cr ₹26.49 Cr ₹12.61 Cr ₹31.04 Cr ₹14.97 Cr ₹9.08 Cr ₹6.85 Cr ₹17.47 Cr ₹7.78 Cr ₹14.34 Cr ₹5.05 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹9.91 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹61.6 Cr ₹33.47 Cr ₹26.49 Cr ₹12.61 Cr ₹31.04 Cr ₹24.88 Cr ₹9.08 Cr ₹6.85 Cr ₹17.47 Cr ₹7.78 Cr ₹14.34 Cr ₹5.05 Cr
Total Tax Expense ₹14.11 Cr ₹7.89 Cr ₹6.36 Cr ₹3.01 Cr ₹7.11 Cr ₹5.28 Cr ₹5.56 Cr ₹5.63 Cr ₹6.96 Cr ₹93 Lakh ₹4.4 Cr ₹3.87 Cr
Net Profit ₹47.49 Cr ₹25.58 Cr ₹20.13 Cr ₹9.6 Cr ₹21 Cr ₹19.6 Cr ₹3.52 Cr ₹1.22 Cr ₹10.51 Cr ₹6.85 Cr ₹9.94 Cr ₹1.18 Cr
  attributable to Owners ₹0 ₹0 ₹0 ₹0 - ₹0 ₹0 ₹0 ₹10.83 Cr ₹0 ₹0 ₹0
  attributable to NCI ₹0 ₹0 ₹0 ₹0 - ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income -₹5.49 Cr ₹1.9 Cr ₹1.26 Cr ₹2.36 Cr -₹81 Lakh -₹1.75 Cr ₹1.84 Cr ₹4 Lakh ₹33 Lakh -₹1.14 Cr -₹12 Lakh -₹36 Lakh
Total Comprehensive Income ₹42 Cr ₹27.48 Cr ₹21.39 Cr ₹11.96 Cr ₹20.19 Cr ₹17.85 Cr ₹5.35 Cr ₹1.26 Cr ₹10.84 Cr ₹5.71 Cr ₹9.82 Cr ₹82 Lakh
EBITDA (computed) ₹68.37 Cr ₹40.04 Cr ₹32.67 Cr ₹18.8 Cr ₹35.76 Cr ₹20.39 Cr ₹15.5 Cr ₹12.85 Cr ₹23.4 Cr ₹14.39 Cr ₹20.84 Cr ₹12.66 Cr
Basic EPS ₹35.53 ₹19.14 ₹15.06 ₹7.18 ₹15.71 ₹14.66 ₹2.63 ₹0.92 ₹7.86 ₹5.13 ₹7.44 ₹0.88
Diluted EPS ₹35.53 ₹19.14 ₹22.24 ₹7.18 ₹15.71 ₹14.66 ₹2.63 ₹0.92 ₹7.86 ₹5.13 ₹7.44 ₹0.88
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹768.73 Cr ₹639.46 Cr ₹575.21 Cr ₹537.66 Cr ₹575.18 Cr ₹514.62 Cr ₹341.46 Cr
Other Income ₹11.45 Cr ₹20.78 Cr ₹11.32 Cr ₹10.17 Cr ₹8.43 Cr ₹17.76 Cr ₹5.31 Cr
Total Income ₹780.18 Cr ₹660.24 Cr ₹586.53 Cr ₹547.83 Cr ₹583.61 Cr ₹532.39 Cr ₹346.77 Cr
Cost of Materials Consumed ₹387.95 Cr ₹348.82 Cr ₹344.15 Cr ₹317.28 Cr ₹372.78 Cr ₹344.04 Cr ₹168.46 Cr
Purchases of Stock-in-Trade ₹10.76 Cr ₹25.04 Cr ₹13.07 Cr ₹5.16 Cr ₹0 ₹0 ₹0
Changes in Inventories -₹11.47 Cr ₹93 Lakh -₹5 Cr ₹14.26 Cr ₹3.19 Cr -₹7.36 Cr ₹5.86 Cr
Employee Benefit Expense ₹84.85 Cr ₹72.24 Cr ₹62.13 Cr ₹51.95 Cr ₹43.75 Cr ₹35.89 Cr ₹46.02 Cr
Finance Costs ₹0 ₹0 ₹0 ₹0 ₹0 ₹12.73 Cr ₹13.34 Cr
Depreciation & Amortisation ₹24.69 Cr ₹21.62 Cr ₹25.55 Cr ₹31.37 Cr ₹32.58 Cr ₹34.28 Cr ₹32.01 Cr
Other Expenses ₹152.72 Cr ₹122.44 Cr ₹99.98 Cr ₹87.48 Cr ₹86.65 Cr ₹95.18 Cr ₹80.31 Cr
Total Expenses ₹649.5 Cr ₹591.09 Cr ₹539.88 Cr ₹507.5 Cr ₹538.94 Cr ₹514.77 Cr ₹345.99 Cr
Profit Before Exceptional Items & Tax ₹130.68 Cr ₹69.15 Cr ₹46.65 Cr ₹40.33 Cr ₹44.67 Cr ₹17.62 Cr ₹77.8 Lakh
Exceptional Items ₹0 ₹9.91 Cr ₹0 ₹0 ₹0 ₹23.44 Cr -₹8.81 Cr
Profit Before Tax ₹130.68 Cr ₹79.06 Cr ₹46.65 Cr ₹40.33 Cr ₹44.67 Cr ₹41.06 Cr -₹8.03 Cr
Total Tax Expense ₹31.37 Cr ₹23.58 Cr ₹16.15 Cr ₹11.37 Cr -₹4.32 Cr -₹13.21 Cr ₹1.96 Cr
Net Profit ₹99.31 Cr ₹52.55 Cr ₹30.5 Cr ₹28.96 Cr ₹48.99 Cr ₹54.27 Cr -₹10 Cr
  attributable to Owners - - - - - - ₹0
  attributable to NCI - - - - - - ₹0
Other Comprehensive Income ₹83 Lakh -₹43 Lakh ₹4 Lakh -₹36 Lakh ₹24.4 Lakh -₹9.5 Lakh -₹47.2 Lakh
Total Comprehensive Income ₹100.14 Cr ₹52.12 Cr ₹30.54 Cr ₹28.6 Cr ₹49.23 Cr ₹54.18 Cr -₹10.47 Cr
EBITDA (computed) ₹155.37 Cr ₹90.77 Cr ₹72.2 Cr ₹71.7 Cr ₹77.25 Cr ₹64.63 Cr ₹46.13 Cr
Basic EPS ₹74.29 ₹39.32 ₹22.82 ₹24.67 ₹37.12 ₹43.97 ₹-8.10
Diluted EPS ₹74.29 ₹39.32 ₹22.82 ₹21.67 ₹37.12 ₹43.97 ₹-8.10
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹876.06 Cr ₹713.22 Cr ₹641.26 Cr ₹608.89 Cr
Non-current Assets ₹470.25 Cr ₹277.47 Cr ₹280.26 Cr ₹290.58 Cr
Current Assets ₹405.81 Cr ₹435.75 Cr ₹361 Cr ₹318.31 Cr
Property, Plant & Equipment ₹110.23 Cr ₹110.93 Cr ₹119.03 Cr ₹121.9 Cr
Inventories ₹129.37 Cr ₹100.49 Cr ₹117.81 Cr ₹113.6 Cr
Trade Receivables ₹116.39 Cr ₹99.26 Cr ₹89.54 Cr ₹84.91 Cr
Cash & Equivalents ₹23.54 Cr ₹55.41 Cr ₹48.51 Cr ₹20.07 Cr
Equity (Net Worth) ₹689.63 Cr ₹589.5 Cr ₹508.59 Cr ₹478.05 Cr
Equity Share Capital ₹13.37 Cr ₹13.37 Cr ₹13.37 Cr ₹13.37 Cr
Borrowings (Non-current) ₹0 ₹0 ₹38.68 Cr ₹38.68 Cr
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹38.68 Cr ₹38.68 Cr
Current Liabilities ₹158.23 Cr ₹105.24 Cr ₹72.81 Cr ₹72.67 Cr
Total Liabilities ₹186.43 Cr ₹123.72 Cr ₹132.67 Cr ₹130.84 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹151.09 Cr ₹83.1 Cr ₹35.38 Cr ₹28.05 Cr ₹40.9 Cr
Investing Cash Flow -₹181.57 Cr -₹76.2 Cr -₹6.95 Cr -₹50.81 Cr -₹16.65 Cr
Financing Cash Flow -₹1.39 Cr ₹0 ₹0 ₹0 -₹9.13 Cr
Capital Expenditure ₹37.66 Cr ₹9.58 Cr ₹9.05 Cr ₹7.8 Cr ₹13.68 Cr
Free Cash Flow (computed) ₹113.43 Cr ₹73.52 Cr ₹26.33 Cr ₹20.25 Cr ₹27.22 Cr
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹31.87 Cr ₹6.9 Cr ₹28.43 Cr -₹22.76 Cr ₹15.12 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹259.01 Cr ₹179.95 Cr ₹192.65 Cr ₹131.85 Cr ₹194.04 Cr ₹172.54 Cr ₹167.02 Cr ₹105.86 Cr ₹175.16 Cr ₹131.23 Cr ₹170.19 Cr ₹98.63 Cr
Other Income ₹4.64 Cr ₹2.41 Cr ₹1.68 Cr ₹8 Cr ₹6.77 Cr ₹1.74 Cr ₹10.71 Cr ₹1.56 Cr ₹3.91 Cr ₹2.42 Cr ₹2.93 Cr ₹2.06 Cr
Total Income ₹263.65 Cr ₹182.36 Cr ₹194.33 Cr ₹139.85 Cr ₹200.81 Cr ₹174.28 Cr ₹177.73 Cr ₹107.42 Cr ₹179.07 Cr ₹133.65 Cr ₹173.12 Cr ₹100.69 Cr
Cost of Materials Consumed ₹116.25 Cr ₹93.86 Cr ₹106.51 Cr ₹71.33 Cr ₹104.21 Cr ₹97.61 Cr ₹77.41 Cr ₹69.59 Cr ₹89.54 Cr ₹87.21 Cr ₹95.18 Cr ₹72.23 Cr
Purchases of Stock-in-Trade ₹4.73 Cr ₹1.9 Cr ₹1.87 Cr ₹2.27 Cr ₹2.13 Cr ₹5.5 Cr ₹8.38 Cr ₹9.03 Cr ₹2.67 Cr ₹2.63 Cr ₹4.6 Cr ₹3.17 Cr
Changes in Inventories -₹1.45 Cr -₹9.51 Cr -₹1.06 Cr ₹55 Lakh -₹4 Cr ₹2.38 Cr ₹23.85 Cr -₹21.3 Cr ₹12.79 Cr -₹6.87 Cr ₹10.17 Cr -₹21.09 Cr
Employee Benefit Expense ₹23.62 Cr ₹19.94 Cr ₹22.03 Cr ₹19.26 Cr ₹19.32 Cr ₹17.39 Cr ₹19.45 Cr ₹16.08 Cr ₹17.21 Cr ₹15.12 Cr ₹16.25 Cr ₹13.55 Cr
Finance Costs ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Depreciation & Amortisation ₹6.5 Cr ₹6.32 Cr ₹5.92 Cr ₹5.95 Cr ₹4.49 Cr ₹5.2 Cr ₹6.17 Cr ₹5.76 Cr ₹5.72 Cr ₹6.3 Cr ₹6.21 Cr ₹7.32 Cr
Other Expenses ₹56.42 Cr ₹37.04 Cr ₹33.46 Cr ₹25.79 Cr ₹49.83 Cr ₹26.75 Cr ₹27.68 Cr ₹18.18 Cr ₹31.68 Cr ₹20.14 Cr ₹30.86 Cr ₹17.3 Cr
Total Expenses ₹206.07 Cr ₹149.55 Cr ₹168.73 Cr ₹125.15 Cr ₹175.98 Cr ₹154.83 Cr ₹162.92 Cr ₹97.34 Cr ₹159.6 Cr ₹124.53 Cr ₹163.27 Cr ₹92.48 Cr
Profit Before Exceptional Items & Tax ₹57.58 Cr ₹32.81 Cr ₹25.6 Cr ₹14.7 Cr ₹24.83 Cr ₹19.45 Cr ₹14.81 Cr ₹10.08 Cr ₹19.48 Cr ₹9.12 Cr ₹9.85 Cr ₹8.21 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹9.91 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹57.58 Cr ₹32.81 Cr ₹25.6 Cr ₹14.7 Cr ₹24.83 Cr ₹29.36 Cr ₹14.81 Cr ₹10.08 Cr ₹19.48 Cr ₹9.12 Cr ₹9.85 Cr ₹8.21 Cr
Total Tax Expense ₹14.11 Cr ₹7.89 Cr ₹6.36 Cr ₹3.01 Cr ₹7.11 Cr ₹5.28 Cr ₹5.55 Cr ₹5.63 Cr ₹6.96 Cr ₹93 Lakh ₹4.4 Cr ₹3.87 Cr
Net Profit ₹43.47 Cr ₹24.92 Cr ₹19.24 Cr ₹11.69 Cr ₹14.79 Cr ₹24.08 Cr ₹9.26 Cr ₹4.45 Cr ₹12.52 Cr ₹8.19 Cr ₹5.45 Cr ₹4.34 Cr
Other Comprehensive Income -₹5.48 Cr ₹2.19 Cr ₹51 Lakh ₹3.61 Cr -₹61 Lakh -₹2.11 Cr ₹2.11 Cr ₹18 Lakh ₹16 Lakh ₹11 Lakh -₹14 Lakh -₹9 Lakh
Total Comprehensive Income ₹37.99 Cr ₹27.11 Cr ₹19.75 Cr ₹15.3 Cr ₹14.18 Cr ₹21.97 Cr ₹11.37 Cr ₹4.63 Cr ₹12.68 Cr ₹8.3 Cr ₹5.31 Cr ₹4.25 Cr
EBITDA (computed) ₹64.08 Cr ₹39.13 Cr ₹31.52 Cr ₹20.65 Cr ₹29.32 Cr ₹24.65 Cr ₹20.98 Cr ₹15.84 Cr ₹25.2 Cr ₹15.42 Cr ₹16.06 Cr ₹15.53 Cr
Basic EPS ₹32.51 ₹18.64 ₹14.40 ₹8.75 ₹11.07 ₹18.02 ₹6.92 ₹3.33 ₹9.36 ₹6.13 ₹4.07 ₹3.25
Diluted EPS ₹32.51 ₹18.64 ₹14.40 ₹8.75 ₹11.07 ₹18.02 ₹6.92 ₹3.33 ₹9.36 ₹6.13 ₹4.07 ₹3.25
Latest 12 quarters shown of 23 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Venus Remedies Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Venus Remedies Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 41.76%, foreign institutional investors hold 2.80%, domestic institutional investors hold 1.20%, retail and other public shareholders hold 54.24% of Venus Remedies Limited. The company had 18,403 shareholders on record.

Promoters: 41.76%DII (Domestic Institutional): 1.20%FII (Foreign Institutional): 2.80%Retail & Others: 54.24%
Mar 2026
QUARTER
41.76% Promoters
1.20% DII (Domestic Institutional)
2.80% FII (Foreign Institutional)
54.24% Retail & Others
Promoter holding - history
Now 41.76% · Mar 2026High 41.76% · Jun 2022Low 32.60% · Dec 2015
31%34%37%40%43%Dec 2015Jun 2018Dec 2020Mar 2023Sep 2025Dec 2015: 32.60%Mar 2016: 32.60%Jun 2016: 32.60%Sep 2016: 32.60%Dec 2016: 32.60%Mar 2017: 37.51%Jun 2017: 37.51%Sep 2017: 37.51%Dec 2017: 37.51%Mar 2018: 37.51%Jun 2018: 37.51%Sep 2018: 37.51%Dec 2018: 37.51%Mar 2019: 37.51%Jun 2019: 37.51%Sep 2019: 35.89%Dec 2019: 35.89%Mar 2020: 35.89%Jun 2020: 35.90%Sep 2020: 35.89%Dec 2020: 35.89%Mar 2021: 35.89%May 2021: 40.81%Jun 2021: 40.81%Sep 2021: 40.81%Dec 2021: 40.81%Mar 2022: 40.81%Jun 2022: 41.76%Sep 2022: 41.76%Dec 2022: 41.76%Mar 2023: 41.76%Jun 2023: 41.76%Sep 2023: 41.76%Dec 2023: 41.76%Mar 2024: 41.76%Jun 2024: 41.76%Sep 2024: 41.76%Dec 2024: 41.76%Mar 2025: 41.76%Jun 2025: 41.76%Sep 2025: 41.76%Dec 2025: 41.76%Mar 2026: 41.76%41.76%32.60%41.76%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters41.76%41.76%41.76%41.76%41.76%41.76%
Public58.24%58.24%58.24%58.24%58.24%58.24%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters41.76%41.76%41.76%41.76%40.81%35.89%35.89%37.51%37.51%37.51%32.60%
Public58.24%58.24%58.24%58.24%59.19%64.11%64.11%62.49%62.49%62.49%67.40%
Promoter change (YoY, %pts)+0.00+0.00+0.00+0.95+4.92+0.00-1.62+0.00+0.00+4.91-

Board & Governance of Venus Remedies Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Venus Remedies Limited has 10 directors - 5 independent and 5 executive. The board is chaired by PAWAN CHAUDHARY.

DirectorPositionOn board sinceListed boards
PAWAN CHAUDHARY Executive Director · MD · Chairperson 1989-09-15 1
MANU CHAUDHARY Executive Director 2005-10-10 1
PEEYUSH JAIN Executive Director 1994-09-28 1
ASHUTOSH JAIN Executive Director 2007-05-01 1
AKSHANSH CHAUDHARY Executive Director 2022-05-27 1
NAVDEEP SUD Non-Executive - Independent Director 2020-06-20 1
SAVITA GUPTA Non-Executive - Independent Director 2021-12-30 1
NPS MONGA Non-Executive - Independent Director 2023-05-29 1
ANIL KUMAR Non-Executive - Independent Director 2024-08-13 1
JAGDISH CHANDER SHARMA Non-Executive - Independent Director 2024-08-13 1
Board Committees
CommitteeMembers
Audit Committee NPS MONGA (Chairperson), NAVDEEP SUD, PAWAN CHAUDHARY
Nomination and remuneration committee SAVITA GUPTA (Chairperson), NAVDEEP SUD, NPS MONGA
Stakeholders Relationship Committee SAVITA GUPTA (Chairperson), NAVDEEP SUD, PEEYUSH JAIN
Corporate Social Responsibility Committee NPS MONGA (Chairperson), ASHUTOSH JAIN, AKSHANSH CHAUDHARY

Charges & Borrowings of Venus Remedies Limited

Open charges
₹0
Satisfied charges
₹909.48 Cr
Breakdown by lending institutions
State Bank of India₹486.64 Cr
Idbi Bank Limited₹82.00 Cr
Dena Bank₹66.50 Cr
Ifci Limited₹50.00 Cr
Export-Import Bank of India₹50.00 Cr
Others₹174.34 Cr
Latest charge details
DateLenderAmountStatus
10 Feb 2015 Idbi Trusteeship Services Limited ₹16.57 Cr Satisfied
31 Mar 2014 Dena Bank ₹2 Cr Satisfied
09 Jan 2014 Andhra Bank ₹5 Cr Satisfied
09 Jan 2014 Andhra Bank ₹20 Cr Satisfied
26 Nov 2013 Dena Bank ₹14.5 Cr Satisfied

Total charge records: 42 View all charges

Employees and EPFO Compliance at Venus Remedies Limited

Venus Remedies Limited has a workforce of 1,119 employees as of Oct 09, 2025.

Employee count
1,119
Active EPFO establishments
2
Employee growth
16.08%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Venus Remedies Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Venus Remedies Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Venus Remedies Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Venus Remedies Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Venus Remedies Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Venus Remedies Limited

MSME Payment Delays by Venus Remedies Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Venus Remedies Limited

Subsidiaries & Group Companies of Venus Remedies Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Venus Remedies Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Venus Remedies Limited

MCA Filings & Documents of Venus Remedies Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Venus Remedies Limited

Activity
22 Aug 2025
Venus Remedies Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records.
Activity
31 Mar 2025
Venus Remedies Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chandigarh.
Directors
13 Aug 2024
Jagdish Chander Sharma was appointed as a Director on 13 Aug 2024 & has been associated with this company since 1 year 10 months.
Directors
13 Aug 2024
Anil Kumar was appointed as a Director on 13 Aug 2024 & has been associated with this company since 1 year 10 months.
Directors
29 May 2023
Npsingh Monga was appointed as a Director on 29 May 2023 & has been associated with this company since 3 years 1 month.
Directors
27 May 2022
Akshansh Chaudhary was appointed as a Whole-time director on 27 May 2022 & has been associated with this company since 4 years 1 month.

Recent News on Venus Remedies Limited

Frequently Asked Questions about Venus Remedies Limited

Venus Remedies Limited is an active public limited company in the pharma sector based in Chandigarh, Chandigarh, India. It was incorporated on 15 September 1989 (37+ years old) and is registered under CIN L24232CH1989PLC009705. Listed on BSE: 526953 and NSE: VENUSREM. The company has 1,119 employees.

Venus Remedies Limited reported revenue of ₹668.84 Cr for FY 2025 (up 9.00% YoY).

The current directors of Venus Remedies Limited are:

The primary industry of Venus Remedies Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Venus Remedies Limited is listed on both BSE (code: 526953) and NSE (symbol: VENUSREM).

Venus Remedies Limited can be reached at the registered office: Sco 857 2Nd Floor C. No. 10 Nac Manimajra, Chandigarh, Chandigarh, India – 160101, or through the website venusremedies.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available